Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors

Core Insights - Evoke Pharma, Inc. has appointed Greg Pyszczymuka to its Board of Directors, effective February 20, 2025, marking the second board member appointment by Nantahala Capital Management, indicating confidence in Evoke's commercial strategy and growth potential [1][3] Company Overview - Evoke Pharma is a specialty pharmaceutical company focused on developing treatments for gastrointestinal diseases, particularly GIMOTI, a nasal spray formulation of metoclopramide for diabetic gastroparesis [4][5] - GIMOTI is the only drug currently approved in the United States for treating gastroparesis, which affects millions of patients globally [5] Leadership Background - Greg Pyszczymuka has extensive experience in pharmaceutical sales and market access, currently serving as Chief Commercial Officer at Aytu BioPharma, where he has driven operational profitability and sustainable revenue growth [2][3] - His previous roles include senior commercial leadership positions at Neos Therapeutics and other pharmaceutical companies, contributing to his expertise in commercial strategy and revenue optimization [3] Strategic Goals - The appointment of Pyszczymuka is expected to enhance Evoke's market presence and shareholder value as the company aims to expand access to GIMOTI [3] - Pyszczymuka expressed enthusiasm about joining Evoke at a pivotal time, highlighting opportunities for further adoption and growth of GIMOTI [4]